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G
lycated hemoglobin (A1C), expressed as a per-
centage of total hemoglobin, results from the
nonenzymatic glycation of hemoglobin mole-
cules. Because this irreversible process is di-
rectly proportional to intracellular glucose concentrations
(which are generally correlated with extracellular glucose
levels), A1C can be used as a marker of average ambient
glycemia over the mean life span of erythrocytes. Absent
alterations in hemoglobin turnover or erythrocyte physiol-
ogy, A1C adequately captures glucose homeostasis in the
organism. Therefore, it has been widely adopted as an
indicator of glycemic control in the treatment of diabetic
patients (1), and it has recently been proposed as a
diagnostic test for diabetes (2).
Variation in A1C is subject to environmental and genetic
determinants. Its heritability (the proportion of the vari-
ance explained by the familial contribution to the trait,
integrating both genetic and early shared environmental
components) nears 40% in the general population (3) and
60% in twin studies (4). The distribution of A1C displays a
long tail to the right, populated by levels of people whose
hyperglycemia signals diabetes. Pharmacological treat-
ment can signiﬁcantly reduce A1C, providing the rationale
for near normalization of A1C as a treatment goal (1). This
is particularly true for insulin as a therapeutic modality:
barring hypoglycemia and other practical limitations, in-
sulin can be gradually raised until the target A1C has been
reached. Thus, presumably higher insulin doses should be
able to overcome most endogenous (i.e., genetic) obsta-
cles to lowering A1C. In the setting of treated A1C,
therefore, the environmental contribution to the trait
acquires a much larger role than that in the native state,
and one might suspect that it could overwhelm any genetic
component (Fig. 1).
It is therefore intriguing that A1C levels are signiﬁcantly
correlated in monozygotic twins whether they are concor-
dant for type 1 diabetes or not (4): in a discordant twin pair
one twin is treated with insulin, whereas the other one
isn’t, and thus this degree of correlation suggests that
genetic contributors to A1C may be detectable despite the
superimposition of a strong environmental modiﬁer. Rig-
orous estimates of heritability of treated A1C, however,
are not available.
In this issue, the Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Compli-
cations (DCCT/EDIC) investigators describe a laborious
attempt to uncover genetic determinants of A1C as a
measure of glycemic control in treated individuals (5). The
DCCT randomized subjects with type 1 diabetes to con-
ventional and intensive treatment (n  667 and 637,
respectively) and demonstrated the beneﬁt of intensive
insulin therapy to prevent diabetes complications (6). Of
note, although insulin therapy in the intensive arm tar-
geted speciﬁc goals, participants randomized to the con-
ventional arm were generally directed to simply avoid
symptoms; this distinction is important because the pres-
ence of genetic variants that raise A1C (or resist its
lowering by insulin) might identify subjects earmarked for
more aggressive treatment regimens, thus obliterating the
very genetic effect under investigation. Such masking by
treatment may be a concern in the intensive arm, but it is
much less so in the conventional arm where participants
did not adjust their insulin dose by glucose self-monitoring
in as many as 82% of their visits.
Paterson et al. report a genome-wide association (GWA)
study for variants associated with glycemic control in
DCCT/EDIC. The primary trait was the mean of quarterly
A1C values measured over 6.5 years of active study. They
ﬁrst performed a full GWA study of 841,000 directly
genotyped or 1.7 million imputed (best-guess genotypes
based on known correlations in the human genome) single
nucleotide polymorphisms (SNPs) for association with
mean A1C, stratiﬁed by intervention arm as well as in the
combined cohort. This yielded 233 SNPs with P 10
4,
which were then tested for association with quarterly A1C
using repeated measures; 13 SNPs reached a P value
10
7 in this second stage. The 13 SNPs were then tested
for association with mean daily glucose and baseline
C-peptide (to conﬁrm a glycemic mechanism), with A1C
repeated measures in the combined cohort (adjusting for
treatment group and testing for interaction with treat-
ment) and with glycemic complications including coro-
nary calcium, neuropathy, hypoglycemia, and time to renal
or retinal complications (in each arm separately). It should
be noted that none of these tests (with the exception of the
separate GWA studies conducted in the intensive and
conventional arms) are independent because they were
performed in the same individuals.
The authors ﬁnd that one SNP (rs1358030) 200 kb
from the SORCS1 gene in chromosome 10 is associated
with A1C at P  7  10
10, a value that exceeds the
prespeciﬁed empirically determined genome-wide signiﬁ-
cance threshold (5  10
8) (7). Although the association
was most evident in the conventional arm, a consistent
nominal association (P  0.01) could also be detected in
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dependent because the same SNP was also associated
with mean glucose (P  2  10
5). Because GWA studies
query hundreds of thousands of genetic variants, type 1
error must be minimized through stringent signiﬁcance
thresholds and convincing replication; the authors there-
fore sought a similar replication cohort in the Genetics of
Kidneys in Diabetes (GoKinD) Study, a case-control col-
lection of patients with type 1 diabetes with and without
diabetic nephropathy. In the control group (851 patients
with type 1 diabetes and normal renal function), rs1358030
again showed a nominal association with A1C (P  0.01),
which was not seen among patients with nephropathy. Of
the other top signals (those with very low P values but not
quite genome-wide signiﬁcant), a region in chromosome 9
deserves mention. SNPs in the BNC2 gene were associated
with A1C in DCCT/EDIC (P 10
7 in the conventional
arm) and also with A1C in a separate meta-analysis of
35,000 nondiabetic individuals performed by the Meta-
Analysis of Glucose and Insulin-related traits Consortium
(MAGIC) investigators (P 10
4). Interestingly, the
SORCS1 SNP did not replicate in MAGIC, and the BNC2
SNPs did not replicate in GoKinD. SNPs in both regions
were associated with diabetes complications in the ex-
pected direction: SORCS1 with hypoglycemia (and less
robustly with both retinopathy and nephropathy) and
BNC2 with microvascular end points.
Several questions emerge from these results: 1) Are the
associations real? That is, can we trust they signify true
genetic effects despite the strong environmental modiﬁer?
2) Do they provide biological insight? 3) What do they
mean in clinical practice?
The authors have tried everything possible, given the
limitations of their unique cohort, to answer the ﬁrst
question in the afﬁrmative. The distribution of association
P values does not reveal any systematic bias. As outlined
above, one key concern in an interventional study is
whether insulin doses may have been raised blindly in
carriers of resistant variants, abolishing the genetic effect:
adjustment for mean insulin dose did not signiﬁcantly
change the results. The P values for association approach
or exceed genome-wide signiﬁcance (for a single scan: two
were conducted here), and some evidence of replication is
welcome. Consistent associations with other traits in the
same cohort are helpful and demonstrate internal consis-
tency but do not provide independent evidence of replica-
tion. It is puzzling that some associations seem to replicate
in one independent sample but not the other: while power
is limiting in GoKinD, it should not be in MAGIC. In either
case, it appears that at the very least the top signals
reported here merit further study.
Biologically, the gene closest to rs1358030 is SORCS1.
As in all association studies, whether rs1358030 represents
the causal SNP or (more likely) is simply correlated with
an ungenotyped causal variant in the region awaits de-
tailed ﬁne-mapping and functional studies; therefore,
SORCS1 may not be the gene that gives rise to the
phenotype. Nevertheless, several features make it an in-
teresting candidate: Attie and colleagues have described a
quantitative trait locus for fasting insulin in the syntenic
region in mice (8), and independent evidence has been
obtained in rats (9). There is modest evidence of genetic
association in two human studies (10,11), albeit not widely
replicated and with variants not correlated to the one
FIG. 1. Simpliﬁed theoretical model illustrating the potential contributors to A1C levels in the native (left) or treated (right) states. The
heritability of native A1C is estimated to be 50%, indicating an approximately even contribution from environmental and genetic factors.
Among the genetic components, processes relevant to glycemic physiology and total hemoglobin levels are both operational; the relative
contribution of each is the subject of active investigation. In diabetes, the disease process (with distinct interacting genetic and environmental
determinants dependent on the type) leads to marked elevations in A1C and, therefore, a large contribution to its variance. Most of that elevation
can be overcome with treatment, which represents a strong environmental modiﬁer whose genetic component is limited to endogenous
pharmacokinetic and pharmacodynamic parameters. In this scenario, uncovering genetic contributors to A1C becomes much more challenging;
how these relate to the genetic variants that underlie native A1C levels is also more difﬁcult to ascertain. RBC, erythrocyte.
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SORCS1 protein product binds to platelet-derived growth
factor-BB, which is required for the recruitment of peri-
cytes to the vascular endothelium. Alterations in that
process could lead to impaired insulin availability in
relevant tissues. With regard to diabetes complications,
SORCS1 is expressed in both the kidney and the retina.
Assuming that the genetic association is real and bio-
logically relevant, the ﬁnal question relates to its signiﬁ-
cance in clinical practice. “Glycemic control” as captured
by A1C is a heterogeneous trait inﬂuenced by individual
responsiveness to insulin (which in turn may be affected
by other variables such as presence of autoantibodies,
BMI, insulin resistance, type of insulin, or mode of admin-
istration), timing of injections, environmental factors (e.g.,
diet and exercise), subject adherence, and prescriber
decisions. On the other hand, the key end point of glyce-
mia is easily and cheaply measured, resistance can be
overcome by simply increasing insulin doses, and many of
the contributing factors mentioned above are likely unre-
lated to this genetic signal; therefore, how this information
could be incorporated by the practitioner is not readily
apparent. Thus, the main contributions of this work may
relate to the development of analytical methods (e.g.,
illustrating the advantages of repeated longitudinal mea-
sures of a quantitative variable as a more stable end point
than a single measurement) and the identiﬁcation of a
pathway potentially relevant to glycemic physiology that
may spawn further research.
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